Immunotech Laboratories BG have begun negotiations in Macedonia and Serbia for Phase III testing on human patients

Immunotech Laboratories, Inc. (IMMB) and Immunotech Laboratories BG recently announced the successful completion of Phase I and Phase II field trials in Bulgaria of the Company’s HIV/AIDS and Hepatitis C virus treatment (“ITV-1 Treatment”) and have begun negotiations for sites in Macedonia and Serbia for Phase III testing on human patients. The clinical test are being conducted through Immunotech Laboratories, BG (“IMMB-BG”) Since 2013 IMMB-BG hired and funded the Clinical Research Organization (“CRO”) to conduct all preclinical and monitoring phase III clinical studies. The product for the Bulgarian study was produce under GMP conditions by a US. Contract Manufacturing Facility.

The successful completion of Phase III clinical study testing would enable Immunotech Laboratories (IMMB) to move forward using the Phase I, II, & III clinical trial results, for the FDA application pertaining to legal use of the treatment for HIV/AIDS and Hepatitis “C” patients in the USA.